Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer

Background Survivin is expressed in prostate cancer (PCa), and its downregulation sensitizes PCa cells to chemotherapeutic agents in vitro and in vivo. Small membrane-bound vesicles called exosomes, secreted from the endosomal membrane compartment, contain RNA and protein that they readily transport via exosome internalization into recipient cells. Recent progress has shown that tumor-derived exosomes play multiple roles in tumor growth and metastasis and may produce these functions via immune escape, tumor invasion and angiogenesis. Furthermore, exosome analysis may provide novel biomarkers to diagnose or monitor PCa treatment. Methods Exosomes were purified from the plasma and serum from 39 PCa patients, 20 BPH patients, 8 prostate cancer recurrent and 16 healthy controls using ultracentrifugation and their quantities and qualities were quantified and visualized from both the plasma and the purified exosomes using ELISA and Western blotting, respectively. Results Survivin was significantly increased in the tumor-derived samples, compared to those from BPH and controls with virtually no difference in the quantity of Survivin detected in exosomes collected from newly diagnosed patients exhibiting low (six) or high (nine) Gleason scores. Exosome Survivin levels were also higher in patients that had relapsed on chemotherapy compared to controls. Conclusions These studies demonstrate that Survivin exists in plasma exosomes from both normal, BPH and PCa subjects. The relative amounts of exosomal Survivin in PCa plasma was significantly higher than in those with pre-inflammatory BPH and control plasma. This differential expression of exosomal Survivin was seen with both newly diagnosed and advanced PCa subjects with high or low-grade cancers. Analysis of plasma exosomal Survivin levels may offer a convenient tool for diagnosing or monitoring PCa and may, as it is elevated in low as well as high Gleason scored samples, be used for early detection.

[1]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[2]  D. Altieri Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.

[3]  A. Vitiello,et al.  Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Joanne L Welton,et al.  Can urinary exosomes act as treatment response markers in prostate cancer? , 2009, Journal of Translational Medicine.

[5]  C. Roehrborn,et al.  Survivin expression is associated with features of biologically aggressive prostate carcinoma , 2004, Cancer.

[6]  M. Vidal,et al.  Exosome Release Is Regulated by a Calcium-dependent Mechanism in K562 Cells* , 2003, Journal of Biological Chemistry.

[7]  S. Shariat,et al.  Les biomarqueurs émergents du diagnostic, du staging et du pronostic du cancer de la prostate , 2011 .

[8]  B. Quah,et al.  The immunogenicity of dendritic cell-derived exosomes. , 2005, Blood cells, molecules & diseases.

[9]  B. Challacombe,et al.  Is there a link between BPH and prostate cancer? , 2012, The Practitioner.

[10]  M. Tsai,et al.  Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. , 1999, Molecular endocrinology.

[11]  B. Kramer,et al.  Screening for prostate cancer with PSA testing: current status and future directions. , 2011, Oncology.

[12]  R. Johnstone,et al.  Exosomes biological significance: A concise review. , 2006, Blood cells, molecules & diseases.

[13]  H. Nagai,et al.  Clinical Relevance of Survivin as a Biomarker in Neoplasms, Especially in Adult T-Cell Leukemias and Acute Leukemias , 2004, International journal of hematology.

[14]  Lars Egevad,et al.  Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers , 2011, Acta oncologica.

[15]  Josiah Ochieng,et al.  Detachment of Breast Tumor Cells Induces Rapid Secretion of Exosomes Which Subsequently Mediate Cellular Adhesion and Spreading , 2011, PloS one.

[16]  Salma Khan,et al.  Survivin is released from cancer cells via exosomes , 2010, Apoptosis.

[17]  Yiwei Li,et al.  Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. , 2004, Neoplasia.

[18]  E. Klein,et al.  Localized prostate cancer: radiation or surgery? , 2003, The Urologic clinics of North America.

[19]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[20]  G. Parmiani,et al.  Tumour-released exosomes and their implications in cancer immunity , 2008, Cell Death and Differentiation.

[21]  F. Castellino,et al.  Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. , 2007, Blood.

[22]  Howell Sb Resistance to apoptosis in prostate cancer cells. , 2000 .

[23]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[24]  M. Loda,et al.  Blood and tissue biomarkers in prostate cancer: state of the art. , 2010, The Urologic clinics of North America.

[25]  A. Chakravarti,et al.  Survivin mediates resistance to antiandrogen therapy in prostate cancer , 2005, Oncogene.

[26]  Y. Sekine,et al.  Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. , 2008, Urology.

[27]  S. Mikolajczyk,et al.  Are multiple markers the future of prostate cancer diagnostics? , 2004, Clinical biochemistry.

[28]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[29]  J. Epstein,et al.  A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. , 2008, The Journal of urology.

[30]  H. El-Attar,et al.  Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[31]  A. Taille,et al.  Urine biomarkers in prostate cancer , 2010, Nature Reviews Urology.

[32]  Graça Raposo,et al.  Exosomal-like vesicles are present in human blood plasma. , 2005, International immunology.

[33]  Ryan M. Williams,et al.  Novel biomarkers and therapeutic targets for prostate cancer. , 2010, Frontiers in bioscience.

[34]  Y. Fradet Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen , 2009, Current opinion in urology.

[35]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[36]  S. Raab A Contemporary Study Correlating Prostate Needle Biopsy and Radical Prostatectomy Gleason Score , 2009 .

[37]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[38]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[39]  X. Hao,et al.  Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. , 2009, Acta biochimica et biophysica Sinica.

[40]  S. Fukuda,et al.  Survivin, a cancer target with an emerging role in normal adult tissues , 2006, Molecular Cancer Therapeutics.

[41]  A. Vickers,et al.  Tumor markers in prostate cancer I: Blood-based markers , 2011, Acta oncologica.

[42]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[43]  Salma Khan,et al.  Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential , 2009, British Journal of Cancer.

[44]  H. Shiina,et al.  Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. , 2004, The Journal of urology.

[45]  M. Mason,et al.  Induction of heat shock proteins in B-cell exosomes , 2005, Journal of Cell Science.

[46]  Guido Jenster,et al.  Exosomes as biomarker treasure chests for prostate cancer. , 2011, European urology.

[47]  G. Parmiani,et al.  Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.